PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.02
D/E ratio under 0.3 - Rock-solid balance sheet territory. Warren Buffett would approve, but check if ROE is being sacrificed. Consider examining Interest Coverage to confirm debt serviceability.
3.80
Net debt 3-4x EBITDA - Concerning leverage levels. Howard Marks would demand exceptional business stability. Essential to verify Debt-to-Equity and Interest Coverage.
-2327.49
Negative coverage (negative EBIT) is a classic Benjamin Graham red flag. While possibly indicating turnaround potential, verify Current Ratio and Net Debt to EBITDA for overall financial health.
1.50
Current ratio 1.5-2.0 - Strong liquidity that Warren Buffett would endorse. Verify Operating Cash Flow to confirm quality of current assets.
No Data
No Data available this quarter, please select a different quarter.